Q3 Earnings Forecast for STOK Issued By HC Wainwright

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.55) for the quarter. HC Wainwright currently has a "Buy" rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics' Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Finally, Chardan Capital reiterated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $23.00.

Stoke Therapeutics Price Performance

STOK stock traded down $0.55 during trading on Friday, reaching $7.74. 1,074,611 shares of the company were exchanged, compared to its average volume of 832,826. The company has a market capitalization of $418.56 million, a price-to-earnings ratio of -3.69 and a beta of 0.99. The company has a 50-day moving average of $9.44 and a two-hundred day moving average of $11.30. Stoke Therapeutics has a twelve month low of $7.22 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its holdings in Stoke Therapeutics by 16.2% in the fourth quarter. California State Teachers Retirement System now owns 32,068 shares of the company's stock worth $354,000 after purchasing an additional 4,468 shares in the last quarter. Toronto Dominion Bank bought a new stake in shares of Stoke Therapeutics in the 4th quarter valued at $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock valued at $1,053,000 after acquiring an additional 52,813 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Stoke Therapeutics by 6.7% during the 4th quarter. Squarepoint Ops LLC now owns 120,242 shares of the company's stock valued at $1,326,000 after acquiring an additional 7,575 shares during the period. Finally, Tang Capital Management LLC bought a new position in Stoke Therapeutics during the fourth quarter worth $3,309,000.

Insider Activity

In related news, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock valued at $143,332. Company insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.